Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGBCP0)

Drug Name

DIPROTIN A Drug Info

Synonyms

diprotin A; MLS002207185; NSC602337; HIV inhibitor; AC1Q5KXE; AC1L1F6Q; DivK1c_000899; CHEMBL158110; SCHEMBL17867000; KBio1_000899; HMS502M21; NINDS_000899; Ile-Pro-Ile, > BDBM50085083; NSC-602337; IDI1_000899; AN-25068; SMR001306756; Bacillus cereus BMF673-RF1 culture filtrate; 2-[[1-(2-amino-3-methyl-pentanoyl)pyrrolidine-2-carbonyl]amino]-3-methyl-pentanoic acid; 2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 94701
ChEBI ID: CHEBI:93213
CAS Number: CAS 90614-48-5
TTD Drug ID: DMGBCP0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[2]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[3]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[4]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[5]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[7]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[8]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[9]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[10]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84.
2	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
3	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
4	Clinical pipeline report, company report or official report of Takeda (2009).
5	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
9	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
10	Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
11	Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.